Cervical Cancer

Breast cancer and cervical cancer screenings declined sharply during the early part of the COVID-19 pandemic, according to CDC data released today.

In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about the OUTBACK trial presented at the ASCO Annual Meeting.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, discussed the OUTBACK trial presented at the ASCO Annual Meeting.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about a study evaluating the optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer.

Less than 10% of Medicaid beneficiaries with systemic lupus erythematosus are vaccinated against preventable diseases such as influenza, herpes zoster, cervical cancer and others, according to data published in Arthritis Care & Research.

Adjuvant chemotherapy following chemoradiation did not prolong OS or PFS compared with chemoradiation alone among women with locally advanced cervical cancer, according to results of the randomized phase 3 OUTBACK study.

New data revealed a decline in cervical cancer but an increase in other HPV-associated cancers over the past 2 decades in the United States. The findings were presented at the virtual ASCO Annual Meeting.

Incidence of cervical cancer declined as rates of other HPV-associated cancers increased significantly in the U.S. from 2001 to 2017, according to a population-based study of trends presented during the virtual ASCO Annual Meeting.

The FDA granted priority review to tisotumab vedotin for treatment of certain women with cervical cancer, according to the agent’s manufacturer.

Women with early cervical cancer who conceived at least 3 months after fertility-sparing surgery had a high live birth rate, according to results presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.